Recent Updates
Recently added Catalysts
ARDX Positive Sentiment Score: 70/100

Ardelyx to Participate at the 2024 Jefferies London Healthcare Conference

Tuesday, November 5, 2024 2 min read
Key Takeaway: Ardelyx, Inc. has announced its participation in the 2024 Jefferies London Healthcare Conference, with key executives set to engage in a fireside chat. The event will take place on November 19, 2024, and will be accessible via webcast through the Ardelyx website. The company continues to focus on innovative medicines that address significant unmet medical needs, boasting two approved products in the U.S. and various global commercialization agreements.

Market Sentiment Analysis

POSITIVE FACTORS

  • Ardelyx is participating in a notable industry conference, which indicates active engagement.
  • The company has two commercial products approved in the U.S., highlighting its successful development.
  • A replay of the panel presentation will be available for public access, indicating transparency.

Full Press Release Details

WALTHAM, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that Michael Raab, President and CEO, Justin Renz, Chief Financial and Operations Officer and Eric Foster, Chief Commercial Officer, will participate in a fireside chat at the 2024 Jefferies London Healthcare Conference on Tuesday, November 19, 2024 at 12:30pm GMT / 7:30am EST in London.
To access the live webcast of the panel presentation please visit the Events and Presentations page within the Ardelyx website at https://ir.ardelyx.com/events-and-presentations. A replay of the panel presentation will be available on the Ardelyx website for 30 days following the event.
Ardelyx was founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA® (tenapanor) and XPHOZAH® (tenapanor). Ardelyx has agreements for the development and commercialization of tenapanor outside of the U.S. Kyowa Kirin commercializes PHOZEVEL® (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been submitted in China with Fosun Pharma. Knight Therapeutics commercializes IBSRELA in Canada. For more information, please visit https://ardelyx.com/ and connect with us on X (formerly known as Twitter), LinkedIn and Facebook.
Investor and Media Contacts:

Frequently Asked Questions

When is Ardelyx's presentation at the Jefferies Conference?

The presentation will be on November 19, 2024, at 12:30pm GMT.

How can I access the Ardelyx webcast?

You can access the webcast on the Events and Presentations page of Ardelyx's website.

What products does Ardelyx have approved in the U.S.?

Ardelyx has two approved products in the U.S.: IBSRELA® and XPHOZAH®.

Who commercializes tenapanor in Japan?

Kyowa Kirin commercializes PHOZEVEL® (tenapanor) for hyperphosphatemia in Japan.

How long will the presentation replay be available?

The replay will be available for 30 days after the event on Ardelyx's website.

Tags: ARDX Viatris Investor Conferences Healthcare Ardelyx Jefferies Conference tenapanor biopharmaceuticals healthcare
Last updated: Nov 5, 2024